Form 13-F position report

SAREPTA THERAPEUTICS INC COM S Call options

Reported by BOOTHBAY FUND MANAGEMENT LLC

Company profile Manager portfolio Source filing
SRPT CUSIP 803607100 Manager CIK 0001549230
Latest reported change

Reported 332,500 underlying shares controlled, down 142,400 (30.0%) from the prior quarter.

Reported value -6.0%; share count -30.0% vs. the prior quarter.

Reduced
% of reported 13F value 0.83% This manager · Q1 2024
Underlying shares 332,500 Quarter-end amount reported
Reported notional value $43,045,450 Underlying-share value; not option premium
Consecutive quarters held 12 Through Q1 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarter Activity Underlying shares Change % of reported 13F Reported notional value Filed
Q4 2025 Reduced 0 -52,100 (-100.0%) 0 $0 2026-02-17
Q3 2025 Reduced 52,100 -66,500 (-56.1%) 0.01% $1,003,967 2025-11-14
Q2 2025 New 118,600 +118,600 (0.0%) 0.04% $2,028,060 2025-08-14
Q1 2025 Reduced 0 -23,400 (-100.0%) 0 $0 2025-05-15
Q4 2024 New 23,400 +23,400 (0.0%) 0.07% $2,845,206 2025-02-14
Q3 2024 Reduced 0 -90,700 (-100.0%) 0 $0 2024-11-14
Q2 2024 Reduced 90,700 -241,800 (-72.7%) 0.34% $14,330,600 2024-08-14
Q1 2024 Reduced 332,500 -142,400 (-30.0%) 0.83% $43,045,450 2024-05-15
Q4 2023 Added 474,900 +250,300 (111.4%) 1.17% $45,794,607 2024-02-14
Q3 2023 Added 224,600 +220,200 (5004.5%) 0.65% $27,226,012 2023-11-14
Q2 2023 Reduced 4,400 -38,200 (-89.7%) 0.01% $503,888 2023-08-14
Q1 2023 New 42,600 +42,600 (0.0%) 0.12% $5,871,558 2023-05-15
Q4 2022 Reduced 0 -11,500 (-100.0%) 0 $0 2023-02-14
Q3 2022 Reduced 11,500 -1,200 (-9.4%) 0.03% $1,271,000 2022-11-14
Q2 2022 New 12,700 +12,700 (0.0%) 0.03% $952,000 2022-08-15
Q1 2022 Reduced 0 -43,000 (-100.0%) 0 $0 2022-05-16
Q4 2021 Added 43,000 +7,000 (19.4%) 0.09% $3,872,000 2022-02-14
Q3 2021 Added 36,000 +30,400 (542.9%) 0.09% $3,329,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history
Institutional context

Who else reported the position

30 managers reported SAREPTA THERAPEUTICS INC COM S for Q1 2024.

Manager Activity Underlying shares Change % of reported 13F Reported notional value Tenure
Logos Global Management LP Added 1,200,000 +500,000 12.57% $155,352,000 2 qtrs
Caption Management LLC Reduced 783,000 -181,300 1.54% $101,367,180 21 qtrs
SUSQUEHANNA INTERNATIONAL GROUP LLP Reduced 712,600 -188,200 0.02% $92,253,196 44 qtrs
Skaana Management L P Added 510,000 +505,000 1.34% $67,228,200 2 qtrs
BOOTHBAY FUND MANAGEMENT LLC This report Reduced 332,500 -142,400 0.83% $43,045,450 12 qtrs
CITADEL ADVISORS LLC Reduced 331,100 -65,700 < 0.01% $42,864,206 31 qtrs
Ikarian Capital LLC Reduced 116,100 -66,500 1.65% $15,030,306 18 qtrs
LMR Partners LLP Reduced 102,900 -91,000 0.14% $13,321,434 4 qtrs
Bank of America Corporation New 99,000 +99,000 < 0.01% $12,816,540 5 qtrs
Parallax Volatility Advisers L P Added 70,300 +41,700 0.02% $9,101,038 19 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2024
Filed
May 15, 2024
Filing type
13F-HR
Position type
Call options

Voting authority reported

Sole
0
Shared
332,500
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.